Heart remodeling after endovascular aortic repair
Official title: Cardiac Remodelling Following Endovascular Repair of the Aorta
Run by Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa · NCT07415447 · Data updated 2026-11-12
We will see if endovascular aortic repair changes heart size, shape, or function in adults treated for aortic aneurysms or related aortic problems.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa Research network |
| Locations | 2 sites (Lisbon and 1 other locations) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | September 1, 2026 |
| Study ends | September 1, 2027 |
| Registry record updated | February 17, 2026 |
| Trial ID | NCT07415447 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) scheduled for elective total EVAR for degenerative aortic aneurysm, penetrating aortic ulcer, or intramural hematoma who do not have major cardiac comorbidities are ideal candidates.
✕Probably not a fit
Patients with significant heart failure, arrhythmias (including atrial fibrillation), advanced valve disease, coronary disease, connective tissue disorders, severe pulmonary disease, or contraindications to CMR are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective observational cohort follows adults undergoing elective total endovascular aortic repair (EVAR) for degenerative thoracic or abdominal aneurysms, penetrating aortic ulcers, or intramural hematomas. Participants receive a baseline clinical exam, blood tests, CT, echocardiography, and cardiac magnetic resonance (CMR) before surgery, with the same imaging and testing repeated at 6 and 12 months after repair. The study measures changes in cardiac morphology and function over time using multimodality imaging and biomarkers. Patients with significant pre-existing cardiac disease, arrhythmias, severe valve disease, prior or expected cardiac/aortic surgery, advanced CKD, or contraindications to CMR are excluded.
Why it matters
Potential benefit: If successful, results could clarify how EVAR affects the heart and help guide follow-up care to prevent or manage post-procedure cardiac problems.
How similar studies have gone: Previous observational work has reported cardiac changes after major aortic procedures, but detailed longitudinal CMR data specifically after EVAR are limited, making this approach partly novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Patients over 18-year-old, with degenerative arch, descending thoracic or abdominal aortic aneurysms, penetrating aortic ulcers or intramural hematomas managed with total EVAR in elective setting. Exclusion Criteria: * Heart failure with an ejection fraction \<35 vs 50% or New York Heart Association (NYHA) class III and IV. * LV wall motion abnormality. * Moderate to severe valve disease. * History of (or expected within the study period) cardiac/aortic surgery. * Coronary artery disease. * Atrial fibrillation. * Congenital heart disease. * Connective tissue disorders. * Chronic kidney disease (eGFR \<30 mL/min/173 m2). * Moderate to severe pulmonary disease as indicate either by post bronchodilator FEV1 (%predicted) \<50% or Modified Medical Research Council Dyspnoea Scale (mMRC) 3-4. * CMR contraindications (non-compatible pacemakers and metal implants, and claustrophobia).
Where it's running
-
Unidade Local de Saúde Santa Maria
Lisbon, Portugal Recruiting -
Unidade Local de Saúde de Santa Maria, E.P.E.
Lisbon, Portugal Not yet recruiting
Study contacts
- Study coordinator: Augusto Ministro Augusto Ministro
- Email: cic@ulssm.min-saude.pt
- Phone: 00531 210405814
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Platelet population changes during ECMO circulatory support
This will test whether the proportions of different platelet types change during ECMO in adults with cardiac or respiratory failure.
-
Personalizing adult heart transplant immunosuppression using blood microRNA levels
This project will try to use blood microRNA patterns to monitor immune status in adults after heart transplant and predict who will develop infection or rejection.
-
Using Landiolol to improve outcomes in mitral valve surgery
This study is testing if the medication Landiolol can help people having mitral valve surgery recover better and have fewer heart problems afterward.
-
Social prescribing to help women with heart failure stick to treatments and avoid hospital visits.
This project will try social prescribing—connecting women with heart failure to community supports—to help them take heart medicines and reduce hospitalizations.
-
Identifying microRNAs to improve heart transplant outcomes in children
This study is trying to find specific microRNAs in the blood of children who have had heart transplants to see if they can help predict infections and rejection of the new heart.
-
Effect of phosphocreatine on patients treated by medical emergency teams
This study tests if giving phosphocreatine to hospitalized patients with serious conditions can help them recover faster and shorten their hospital stays compared to those who receive a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.